President Donald Trump demands drugmakers match global prices or face federal action, citing abusive pricing and pledging to protect American patients.

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

President Donald Trump surprised pharma CEOs on Thursday with letters demanding they acquiesce to his most-favored drug-pricing scheme (see what we did there?) by the end of September, setting up a late-summer lobbying fight for the industry.